"As adults, too many of us have learned over time to neglect our creative selves because we don't feel we have the time, ...

Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Maze Therapeutics (NASDAQ:MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced ...

Just kidding, all you need to do is click your mouse, and your avatar will do all the walking in the Maze Simulator. You can never be entirely sure you’ve typed in a code correctly if you’re ...

Welcome to the new series from the Jewish Children's Museum in conjunction with COLlive: “History’s Heroes,” where we learn about our favorite Jewish Heroes and craft, paint, or experiment, along the ...